AndhraNews.net
Home » Business News » 2012 » November » November 2, 2012

PropThink: ArQule Reports 3Q Results as Investors Now Look to Tivantinib's HCC Indication


November 2, 2012 -

By Jake King
Oncology-focused ArQule, Inc. (NASDAQ:ARQL) reported third quarter financial results on Thursday morning, noting that cash, equivalents, and marketable investts totaled $140M on Sept. 30, and that the company will likely end the year with close to $130M. ArQule performed a bit better financially than expected in the quarter, but importantly, the company is guiding for FY12 net loss per share in the range of $.20 to $.25, in-line with analyst estimates.
The company has recently faced some headwinds. ArQule's Japanese partner Kyowa Hakko Kirin suspended a Japanese Phase 3 non small-cell lung cancer trial of tivantinib in August due to safety concerns. And in early October, ArQule announced that its lead development program in the West (partnered with Daiichi Sankyo [OTC:DSKYF]), also evaluating tivantinib as a treatment for NSCLC, would not meet its primary endpoint; the Phase III MARQUEE trial was halted for futility. It is important to note that the MARQUEE trial demonstrated no safety issues. The stock sold off by almost 70% as investors discounted tivantinib's NSCLC indication. (Read more here.)
The company now pins tivantinib's future on a planned Phase III trial for hepatocellular carcinoma (HCC, or liver cancer) and a Phase II trial for colorectal cancer (CRC). The CRC trial is expected to show clinical results by the end of the year. On Thursday's conference call, management, however, focused almost exclusively on the HCC indication, and questions from analysts demonstrated that the CRC indication is not the top priority at the moment, considering that it is only in Phase II. Because ArQule is set to release data from the CRC trial in the coming months, and there is little value being assigned to this indication, investors may be able to get a ""free"" look at Phase II data with limited downside risk. With a $156M market capitalization, the company trades with an enterprise value of just over $15M (technology value), with most, if not all, of the value assigned to the potential HCC indication. Given that tivantinib has shown activity in multiple cancer indications, the low price of the stock presents an opportunity to own a promising compound on the cheap.
ArQule and the FDA have agreed to a Special Protocol Assessment for tivantinib's upcoming HCC trial, and management hopes to begin treating the first patient by the end of the year or in early 2013. The trial won't be completed for at least another year, likely two, so any related value-driving events for the HCC indication, aside from trial initiation, won't materialize in the near-term. Management did say that of ArQule's four early-stage candidates, it will likely partner one or more based on early trial data as it becomes available. ArQule's partnership with Daiichi has been lucrative and crucial to ongoing tivantinib development; if it can secure a similar partnership for another compound, the benefits could be meaningful.
With risk somewhat limited by ArQule's healthy balance sheet, a long-term position based on tivantinib in HCC - with the possibility of unexpected upside should the CRC trial demonstrate promise - might make sense. The market for a quality second-line HCC treatment is lucrative as the drug could fulfill an unmet medical need. The FDA's expressed confidence in the trial also lends credibility to its design, although an SPA is far from determinant. Thursday morning, the stock gained slightly, and should maintain strength as the CRC trial results come into view.
Read this article in its original form by clicking here.
About PropThink
PropThink is an intelligence service that delivers long and short trading ideas to investors in the healthcare and life sciences sectors. Our focus is on identifying and analyzing technically-complicated companies and equities that are grossly over or under-valued. We offer daily market coverage, weekly feature stories, and a newsletter to investors who subscribe on PropThink.com. To learn more, follow us on Twitter or visit us at http://www.propthink.com.
Disclaimer:
You should assume that as of the publication date of any report or letter, PropThink, LLC and persons or entities with whom it has relation ships (collectively referred to as ""PropThink"") has a position in all stocks (and/or options of the stock) covered herein that is consistent with the position set forth in our research report. Following publication of any report or letter, PropThink intends to continue transacting in the securities covered herein, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. To the best of our knowledge and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and not from company insiders or persons who have a relationship with company insiders. PropThink was not compensated to publish this article. Our full disclaimer is available at http://www.propthink.com/disclaimer.




This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.

Source: PropThink via Thomson Reuters ONE

HUG#1654487

Copyright 2012 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

ACN Newswire

Comment on this story

Share